Cetuximab (anti-EGFR)

製品コード：A2000         Batch: A200010

印刷

Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW : 145.781 KD.

製品説明

CAS No. 205923-56-4
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99%
Protein concentration 4.95mg/ml
Endotoxin Level ＜1EU/mg

カスタマーフィードバック

数据来源于[Data independently produced by , , J Thorac Oncol, 2018, 13(6):810-820]

Mice showed progression disease to first-line treatment were randomized 1:1 to the two arms of treatment and were treated until onset of progression disease or until the end-time of experiment in case of response (fixed to 52 weeks from the start of first-line therapy ), as indicated in in the Materials and Methods section. Growth curves of HCC827 xenografts treated in secondline with osimertinib plus selumetinib or cetuximab are represented as changes in the values of volumes as percentage compared to baseline tumor volume at the time of progression diasease to first-line (defined as 100%) for each case. Median tumor volume at PD2 was of 348 mm3.

数据来源于[Data independently produced by , , ]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

The effector program of human CD8 T cells supports tissue remodeling [ J Exp Med, 2024, 221(2)e20230488] PubMed: 38226976
Differential Regulation of the STING Pathway in Human Papillomavirus-Positive and -Negative Head and Neck Cancers [ Cancer Res Commun, 2024, 4(1):118-133] PubMed: 38147007
Double Digital Assay for Single Extracellular Vesicle and Single Molecule Detection [ Adv Sci (Weinh), 2023, 10(33):e2303619] PubMed: 37802976
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer [ Oncogene, 2023, 42(20):1620-1633] PubMed: 37020035
EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer [ Mol Cell Proteomics, 2023, 22(9):100624] PubMed: 37495186
EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer [ Mol Cell Proteomics, 2023, 22(9):100624] PubMed: 37495186
Development of New Targeted Nanotherapy Combined with Magneto-Fluorescent Nanoparticles against Colorectal Cancer [ Int J Mol Sci, 2023, 24(7)6612] PubMed: 37047582
Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior [ Biomolecules, 2023, 13(11)1647] PubMed: 38002329
3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis [ Cancer Gene Ther, 2023, 30(10):1414-1425] PubMed: 37558749
Development of a new minimally invasive phototherapy for lung cancer using antibody-toxin conjugate [ Thorac Cancer, 2023, 14(7):645-653] PubMed: 36655546

人間や獣医の診断であるか治療的な使用のためにでない。